EPHB2 and pachyonychia congenita: EphB2 expression was frequently found to be decreased in prostate cancer (PC) tissues with somatic mutational inactivation occurred in approximately 10% of sporadic tumors (Huusko et al., 2004; Robbins et al., 2011).